[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]

Ken Takase, Toshihiro Miyamoto

研究成果: Contribution to journalArticle

抜粋

In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.

元の言語英語
ページ(範囲)107-113
ページ数7
ジャーナルNihon rinsho. Japanese journal of clinical medicine
73
発行部数1
出版物ステータス出版済み - 1 1 2015

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント [Allogeneic hematopoietic stem cell transplantation for multiple myeloma]' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用